Afaghi, 646 patient vitamin D sufficiency study: 55% lower mortality [p=0.002], 56% lower ventilation [p<0.0001], and 34% lower ICU admission [p=0.0001] https://c19p.org/afaghi
copied to clipboard
Prevalence and Clinical Outcomes of Vitamin D Deficiency in COVID-19 Hospitalized Patients: A Retrospective Single-Center Analysis
et al., The Tohoku Journal of Experimental Medicine, doi:10.1620/tjem.255.127
Retrospective 646 COVID-19+ hospitalized patients in Iran, showing higher mortality with vitamin D deficiency.
|
risk of death, 55.0% lower, RR 0.45, p = 0.002, high D levels 97 of 537 (18.1%), low D levels 51 of 109 (46.8%), NNT 3.5, adjusted per study, odds ratio converted to relative risk, >20ng/mL, multivariate.
|
|
risk of mechanical ventilation, 55.9% lower, RR 0.44, p < 0.001, high D levels 89 of 537 (16.6%), low D levels 41 of 109 (37.6%), NNT 4.8, >20ng/mL, unadjusted.
|
|
risk of ICU admission, 34.1% lower, RR 0.66, p < 0.001, high D levels 211 of 537 (39.3%), low D levels 65 of 109 (59.6%), NNT 4.9, >20ng/mL, unadjusted.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Afaghi et al., 10/12/2021, retrospective, Iran, Middle East, peer-reviewed, 7 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.